

Special Issue

Innovation in Neuromodulation and Translational Neuroscience

Message from the Guest Editor

We are excited to invite you to the III Symposium on Innovation and Translational Neuroscience & XVI International Symposium on Neuromodulation, taking place from August 15th to 19th, 2024, in São Paulo, Brazil. This conference seeks to advance scientific research in the field of neuromodulation, focusing on its mechanisms and therapeutic applications and the identification and utilization of biomarkers.

In conjunction with the symposium, we are preparing a Special Issue to showcase the groundbreaking research and developments in neuromodulation discussed during the event. We are grateful for the substantial support from esteemed colleagues such as /Kevin Pacheco-Barrios (Harvard University, EUA), Dr. Olivia Lapenta (Minho University, Portugal), Dr. Fernando Zanela da Silva Arêas (Baylor Scott & White Research Institute, Baylor University), and Prof. Marília Lira (Mackenzie University, Brazil).

We are calling for submissions of original research articles, thorough reviews, and insightful papers on the following topics: Mechanisms of action in neuromodulation; Therapeutic applications of neuromodulation; Biomarkers in neuromodulation research.

Guest Editor

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Deadline for manuscript submissions

closed (30 November 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/209498

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).